Stroke, Statins, and Cholesterol. A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials With HMG-CoA Reductase Inhibitors

摘要: Background and Purpose To estimate the effect of 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors (“statins”) on stroke risk, we combined data randomized, placebo-controlled, double-blind trials with HMG-CoA published so far. Methods The studies were identified using Medline CD+ Current Contents databases from January 1980 through May 1996, inclusive. All evaluated use a placebo control, monotherapy, double blindness. When type or occurrence clinical events adverse effects incompletely not reported, investigators contacted personally. For each trial, number strokes in treatment arm was compared expected all observations under assumption that drug had no effect. Results total 462 among 20 438 participants 13 could be analyzed. 181 observed patients randomized to an inhibitor 261 placebo. lower than groups but one trial ( P =.001). Treatment led overall risk reduction 31% (odds ratio, 0.69; 95% confidence interval, 0.57 0.83). Conclusions suggest prevents middle-aged persons. Because is especially common older age, these reinforce need for evaluate preventing elderly.